Sector News

Investors: GSK chief Witty is safe for now, but one more strike and he’s out

May 26, 2015
Life sciences
As GlaxoSmithKline charts a new course to return to growth, investors are willing to give CEO Andrew Witty some time to see it through.
 
But if any more setbacks turn up? He could be out of there, top shareholders told the Financial Times.
 
“With shares badly underperforming, there need to be some positive signs soon, or pressure could build up against the chief executive,” a top-20 GSK shareholder told the paper. “The company says growth will revive by next year. They have to achieve that.”
 
That puts quite a bit of pressure on the volume-based sales strategy the company rolled out earlier this month. The plan involves hawking lower-margin products–like vaccines and OTC products, two areas GSK put its faith in with this year’s blockbuster Novartis asset swap–in high numbers.
 
That way, the company can avoid pricing pressures facing drugs like Advair, whose unfavorable formulary placement has sent sales sputtering as of late. Glaxo won’t be “fixated on defending ever and ever higher prices in the developed world,” Witty recently told CNBC, and he expects the new strategy to deliver consumer health sales growth in the mid-single digits and vaccine sales expansion in the mid-to-high-single digits at a compound annual rate between 2016 and 2020.
 
As one investor pointed out to the FT, though, to achieve that will take quite a bit of volume. Plus, Advair–whose freefall is expected to worsen once U.S. generics hit, a prospect the British pharma giant acknowledges could come sooner rather than later–will leave big shoes to fill.
 
“Putting your faith in over-the-counter goods like toothpaste is a gamble,” the shareholder said.
 
So how long will investors be willing to wait, without some proof the new tactics are working? According to one top-10 investor, less than two years should do it, or Witty needs to go.
 
“I think Witty needs to be given 18 months to prove himself,” that investor told the Times.
 
But before that mark, Glaxo may find some deal potential on its hands. Last week, analysts speculated the company could make a good match for deal-hungry Pfizer, which has been scouting large transactions since last year’s failed attempt at snatching up rival AstraZeneca.
 
By Carly Helfand
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.